Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
Get a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Recombinant Humanized Antibody scFv Fragment binds selectively to HIV-1, expressed in E. coli
scFv Fragment from Humanized IgG1 - kappa
The details of the immunogen for this antibody are not available.
Suitable for use in ELISA, WB, Neut and most other immunological methods.
>95.0% as determined by Analysis by RP-HPLC & analysis by SDS-PAGE.
Store at 4°C for up to 3 months. For longer term storage aliquot into small volumes and store at -20°C.
This antibody is an antiviral and immunomodulator.
HIV is a highly variable virus which mutates very readily. This means there are many different strains of HIV, even within the body of a single infected person. The strains of HIV1 can be classified into three groups : the "major" group M, the "outlier" group O and the "new" group N. These three groups may represent three separate introductions of simian immunodeficiency virus into humans. Group O appears to be restricted to West-Central Africa and group N, discovered in 1998 in Cameroon, is extremely rare. More than 90% of HIV1 infections belong to HIV1 group M.